Daiichi Sankyo/AstraZeneca Get Two Lucky Breaks For Enhertu
Executive Summary
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
You may also be interested in...
AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
Read-Outs To Look Out For At ESMO Cancer Congress
The European cancer congress returns in-person, with companies big and small presenting new agents and combinations across tumor types.
AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.